Time to Move to Targeted Drugs in Biliary Tract Cancer?

Publisher： Karger

E-ISSN： 2296-5262|33|1-2|10-11

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.1-2, 2010-01, pp. : 10-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Novel diagnostic and prognostic biomarkers in biliary tract cancer

By Skipworth James RA   Timms John F   Pereira Stephen P  

Expert Opinion on Medical Diagnostics, Vol. 7, Iss. 5, 2013-09 ,pp. : 487-499

Informa Healthcare

Access to resources Recommend Favorite

S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 71-74

Karger

Access to resources Recommend Favorite

Patterns of Initial Disease Recurrence after Resection of Biliary Tract Cancer

By  

Oncology, Vol. 83, Iss. 2, 2012-07 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer

By  

Oncology, Vol. 89, Iss. 6, 2015-09 ,pp. : 345-350

Karger

Access to resources Recommend Favorite

Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 1-2, 2010-01 ,pp. : 45-47

Karger

Access to resources Recommend Favorite